QTNT - Quotient gains 23% on announcing prelim Q4 and FY22 revenue above consensus
Quotient (NASDAQ:QTNT) +23% on expecting reagent business generated product sales of $9.8M ($8.18M consensus) in Q4 and FY22 revenue of $38.5M ($36.89M consensus). The Company recently secured $1.4 million of orders in the first quarter of fiscal year 2023 for its recently CE Marked Extended Immunohematology MosaiQ solution. $83.2 million in cash and investments as of March 31, 2022 The Company will release its financial results and host a conference call before market open on Friday, June 24, 2022.
For further details see:
Quotient gains 23% on announcing prelim Q4 and FY22 revenue above consensus